戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 humans, responsible for approximately 20% of disseminated candidiasis.
2  important determinant of host resistance to disseminated candidiasis.
3 e role of ICAM-1 in the host defense against disseminated candidiasis.
4 primary causative agent of oropharyngeal and disseminated candidiasis.
5  EphA2 promotes renal immunopathology during disseminated candidiasis.
6 nal barriers into the bloodstream leading to disseminated candidiasis.
7 , from superficial mucosal to hematogenously disseminated candidiasis.
8  GI tract, a risk factor for haematogenously-disseminated candidiasis.
9 ) for the treatment of experimental subacute disseminated candidiasis.
10 were indistinguishable during hematogenously disseminated candidiasis.
11 cule intervention to improve the outcomes of disseminated candidiasis.
12 howed reduced virulence in a murine model of disseminated candidiasis.
13 ortant for host resistance to hematogenously disseminated candidiasis.
14 sted the susceptibility of CCR5(-/-) mice to disseminated candidiasis.
15 roducts were efficacious in a mouse model of disseminated candidiasis.
16 dhesin, Als3p (rAls3p-N), protects mice from disseminated candidiasis.
17  intravascular catheter biofilm infection or disseminated candidiasis.
18  of host-directed compounds for treatment of disseminated candidiasis.
19 the bloodstream of rabbits with experimental disseminated candidiasis.
20 creased resistance of mice to hematogenously disseminated candidiasis.
21 -N) modestly improves survival during murine disseminated candidiasis.
22  physiological characteristics during murine disseminated candidiasis.
23 ty of human diseases such as oral thrush and disseminated candidiasis.
24 valuated in a murine model of hematogenously disseminated candidiasis.
25 ntial therapeutic target for protection from disseminated candidiasis.
26  immunization strategies to prevent or treat disseminated candidiasis.
27 prophylactic or therapeutic strategy against disseminated candidiasis.
28 mucocutaneous infections like oral thrush to disseminated candidiasis.
29 virulence factors relevant to hematogenously disseminated candidiasis.
30 ever, highly attenuated in a murine model of disseminated candidiasis.
31 virulence of C. albicans in a mouse model of disseminated candidiasis.
32 esponses in a murine model of hematogenously disseminated candidiasis.
33 ogenesis, adherence, and mortality in murine disseminated candidiasis.
34 the role of the MR in immune response during disseminated candidiasis.
35 nd leukocyte adhesion molecules in mice with disseminated candidiasis.
36 ulence in the mouse model of haematogenously disseminated candidiasis.
37 virulence of C. albicans in a mouse model of disseminated candidiasis.
38 e critical for virulence in a mouse model of disseminated candidiasis.
39 antibody enhanced resistance of mice against disseminated candidiasis.
40 ace mannan epitope, does not protect against disseminated candidiasis.
41 nfection in a murine model of hematogenously disseminated candidiasis.
42 albicans in a murine model of hematogenously disseminated candidiasis.
43 or mice in an intravenous infection model of disseminated candidiasis.
44 ice to produce protective antibodies against disseminated candidiasis.
45 ere combined immunodeficiency SCID mice from disseminated candidiasis (100% survival in BCG-vaccinate
46                           In human patients, disseminated candidiasis, a life-threatening disease for
47                          In a mouse model of disseminated candidiasis, a YHB1 deleted C. albicans str
48 cate that the murine model of hematogenously disseminated candidiasis accurately recapitulates the pr
49 ia is the most diagnosed manifestation, with disseminated candidiasis affecting single or multiple or
50 tive antibody responses against experimental disseminated candidiasis and Candida vaginal infection.
51 n, leading to disease manifestations such as disseminated candidiasis and chronic mucocutaneous candi
52 the survival of neutropenic mice with lethal disseminated candidiasis and inhalational aspergillosis.
53  Candida parapsilosis is a frequent cause of disseminated candidiasis and is associated with signific
54 virulent in a murine model of hematogenously disseminated candidiasis and less able to adhere to huma
55  also improves survival of outbred mice from disseminated candidiasis and that it is active against m
56 irulence in a murine model of hematogenously disseminated candidiasis and that strains with each gene
57 essential for virulence in a mouse model for disseminated candidiasis and that the cellular functions
58 hat Als protein production was widespread in disseminated candidiasis and that, despite strain differ
59 ion of mouse antibodies that protect against disseminated candidiasis and vaginal infection.
60 virulence in a mouse model of hematogenously disseminated candidiasis, and for potentiating resistanc
61 uired for full virulence in a mouse model of disseminated candidiasis, and Git3 sequence orthologs ar
62 sal of the blood vessel wall by yeast during disseminated candidiasis, and N-WASP may play a key role
63                     Because risk factors for disseminated candidiasis are well defined and frequently
64 rs are safe and as effective in experimental disseminated candidiasis as once-daily therapy in neutro
65 ficient mice had increased susceptibility to disseminated candidiasis, as indicated by decreased surv
66                        During hematogenously disseminated candidiasis, bloodborne Candida albicans in
67 was equally as effective as rAls1p-N against disseminated candidiasis but was more effective than rAl
68 rs did not correlate with protection against disseminated candidiasis, but delayed-type hypersensitiv
69 on gamma (IFN-gamma) in host defense against disseminated candidiasis, but in vivo studies are inconc
70 w that neutrophils mediate renal immunity to disseminated candidiasis by upregulating glucose uptake
71            In in vivo experimental models of disseminated candidiasis, C. auris was less virulent tha
72                                      Chronic disseminated candidiasis (CDC) is a form of Candida spec
73                                      Chronic disseminated candidiasis (CDC) is a rare disease that mo
74 ation of lymphoreticular malignancy, chronic disseminated candidiasis (CDC), and from a neutropenic-r
75 ch was shown to contribute to hematogenously disseminated candidiasis (DC) after several days in the
76 ri7 strain M1 underwent filamentation during disseminated candidiasis (DC) in mice.
77 cate C. albicans NOT5 in the pathogenesis of disseminated candidiasis (DC) induced by intravenous inf
78 ere significantly higher among patients with disseminated candidiasis (DC) or oropharyngeal candidias
79 FTNx is highly effective in a mouse model of disseminated candidiasis, demonstrating diminished funga
80                     Mice with hematogenously disseminated candidiasis died of progressive sepsis, as
81  single large dose of micafungin could clear disseminated candidiasis, even though the micafungin hal
82                                              Disseminated candidiasis has become one of the leading c
83  analysis of a mouse model of hematogenously disseminated candidiasis (HDC) and episodes of vulvovagi
84  more resistant to experimental hematogenous disseminated candidiasis if they received MAb B6.1 befor
85 d that MBL therapy may be a means to prevent disseminated candidiasis in high-risk patients.
86  is dispensable for the host defense against disseminated candidiasis in immunocompetent mice.
87 st a fungal disease have been used to combat disseminated candidiasis in mice.
88 E) is a relatively frequent manifestation of disseminated candidiasis in neonates and is associated w
89 b) B6.1 increases resistance to hematogenous disseminated candidiasis in normal and SCID mice.
90                            A murine model of disseminated candidiasis involving intranasal challenge
91                The mortality attributable to disseminated candidiasis is 40 to 50% despite antifungal
92 ultures in patients at risk for hematogenous disseminated candidiasis is controversial.
93           The murine model of hematogenously disseminated candidiasis is the standard for investigati
94 ts role in host resistance to hematogenously disseminated candidiasis is unknown.
95 orter strains were inoculated into mice in a disseminated candidiasis model, and GFP production was m
96 ses are organ and cell type specific, during disseminated candidiasis myeloid cells exacerbate collat
97 ant role in murine resistance to gastric and disseminated candidiasis of endogenous (intestinal tract
98  respectively, were found to be resistant to disseminated candidiasis of endogenous origin and to acu
99 ibodies, were as resistant to orogastric and disseminated candidiasis of endogenous origin as were im
100  required for the normal host defense during disseminated candidiasis or for the phagocytosis of C. a
101 BL-A deficiency does not alter resistance to disseminated candidiasis or initial hepatic invasion by
102  and rabbits with persistent neutropenia and disseminated candidiasis, otherwise fatal, demonstrated
103 cantly protected mice against hematogenously disseminated candidiasis (P = .001).
104 cells and attenuated mortality during murine disseminated candidiasis, proving that our strategy can
105  the molecular basis of host defense against disseminated candidiasis remains elusive, and treatment
106                         In a murine model of disseminated candidiasis, serum Cu was seen to progressi
107                                 Rabbits with disseminated candidiasis showed a steady increase of det
108  released into the bloodstream of hosts with disseminated candidiasis, that phagocytic cells may play
109                            A murine model of disseminated candidiasis was utilized to determine wheth
110 ssessed in a murine model for hematogenously disseminated candidiasis, was significantly attenuated c
111 al antibody (MAb) B6.1 protects mice against disseminated candidiasis, whereas the IgM MAb B6 does no
112 ibe here experiments using a murine model of disseminated candidiasis which demonstrate that in three
113 ncidence of life-threatening, hematogenously disseminated candidiasis, which is predominantly caused
114 s mutants was unimpaired in a mouse model of disseminated candidiasis, while M-2 and CA-2 were 2 orde
115 tenuation in a mouse model of hematogenously disseminated candidiasis, while the double mutant was ra

 
Page Top